Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
Nakamura N, Kanemura N, Matsumoto T, Nakamura H, Ikoma Y, Shibata Y, Kitagawa J, Kasahara S, Yamada T, Sawada M, Kaneda Y, Fukuno K, Takada E, Goto H, Lee S, Fujita K, Morishita T, Hara T, Tsurumi H, Shimizu M. Nakamura N, et al. Among authors: sawada m. Sci Rep. 2023 Nov 4;13(1):19060. doi: 10.1038/s41598-023-46501-5. Sci Rep. 2023. PMID: 37925551 Free PMC article.
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H. Sawada M, et al. Eur J Haematol. 2002 Jun;68(6):354-61. doi: 10.1034/j.1600-0609.2002.01654.x. Eur J Haematol. 2002. PMID: 12225393 Free article. Clinical Trial.
Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H. Tsurumi H, et al. Among authors: sawada m. J Cancer Res Clin Oncol. 2004 Feb;130(2):107-13. doi: 10.1007/s00432-003-0508-9. Epub 2003 Nov 27. J Cancer Res Clin Oncol. 2004. PMID: 14648210 Clinical Trial.
Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H. Goto H, et al. Among authors: sawada m. J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9. doi: 10.1007/s00432-004-0600-9. Epub 2004 Oct 21. J Cancer Res Clin Oncol. 2005. PMID: 15503137
Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M, Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Kojima Y, et al. Among authors: sawada m. Eur J Haematol. 2006 Jun;76(6):465-72. doi: 10.1111/j.1600-0609.2006.00631.x. Epub 2006 Feb 23. Eur J Haematol. 2006. PMID: 16494623 Free article.
1,309 results